Page last updated: 2024-10-23

azasetron and Liver Neoplasms

azasetron has been researched along with Liver Neoplasms in 2 studies

azasetron: a selective 5-HT3 receptor antagonist; structure given in first source;

Liver Neoplasms: Tumors or cancer of the LIVER.

Research Excerpts

ExcerptRelevanceReference
"We performed a clinical evaluation on the antiemetic profile and the plasma concentration of Azasetron Hydrochloride (a new selective 5-HT3 receptor antagonist), in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma."9.08[Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma]. ( Beppu, T; Doi, K; Egami, H; Kudo, S; Kuramoto, M; Masuda, Y; Matsuda, T; Ogawa, M; Ohara, C; Yamanaka, T, 1998)
"We performed a clinical evaluation on the antiemetic profile and the plasma concentration of Azasetron Hydrochloride (a new selective 5-HT3 receptor antagonist), in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma."5.08[Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma]. ( Beppu, T; Doi, K; Egami, H; Kudo, S; Kuramoto, M; Masuda, Y; Matsuda, T; Ogawa, M; Ohara, C; Yamanaka, T, 1998)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hashizume, J1
Higuchi, N1
Sato, K1
Kodama, Y1
Matsunaga, N1
Sakamoto, T1
Yamaguchi, K1
Nakamura, T1
Kitahara, T1
Sasaki, H1
Beppu, T1
Ogawa, M1
Yamanaka, T1
Egami, H1
Ohara, C1
Masuda, Y1
Kudo, S1
Kuramoto, M1
Doi, K1
Matsuda, T1

Trials

1 trial available for azasetron and Liver Neoplasms

ArticleYear
[Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:8

    Topics: Aged; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepato

1998

Other Studies

1 other study available for azasetron and Liver Neoplasms

ArticleYear
Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bridged Bicyclo Comp

2016